Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

“We stumbled into one room that was set up, sort of like a lab,” said Johnie Carter ... Counterfeit versions of Wegovy or Zepbound are different from compounded weight loss drugs.

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.